PFS for BMI groups separated by disease status. PFS for the normal weight, overweight, and obese groups separated by patients with extramedullary disease at time of CAR T-cell therapy (A), without extramedullary disease at time of CAR T-cell therapy (B), with a history of AHCT prior to CAR T-cell therapy (C), without a history of AHCT prior to CAR T-cell therapy (D), with a history of ≥5 lines of therapy prior to CAR T-cell therapy (E), with a history of ≤4 lines of therapy prior to CAR T-cell therapy (F), who received idecabtagene vicleucel (G), who received ciltacabtagene autoleucel (H), or who received an investigational BCMA-targeted CAR T-cell product (I). P value (log-rank) is shown.